Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Werte in diesem Artikel
On February 17, 2026, Commodore Capital disclosed in an SEC filing that it sold out its entire 3,200,000-share position in Viridian Therapeutics (NASDAQ:VRDN), an estimated $69.06 million transaction based on last-disclosed position values.According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital reported selling its entire 3,200,000-share stake in Viridian Therapeutics. The net position change for the quarter was $69.06 million, reflecting the removal of the holding from the portfolio.Viridian Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of innovative antibody-based therapies for serious diseases, with a lead focus on thyroid eye disease. The company leverages expertise in monoclonal antibody engineering to advance its pipeline and address unmet medical needs in rare disorders. With a growing portfolio and a targeted approach to specialty markets, Viridian aims to establish a competitive position in the biotechnology sector through differentiated therapeutics and clinical progress.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Übrigens: Viridian Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Viridian Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Viridian Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool